PMC

The comparison of the achievement of LLDAS and the improvement of SLE parameters between belimumab and telitacicept treatment. Kaplan-Meier curves showing LLDAS achievement in patients after belimumab or telitacicept treatment after a 24 weeks follow-up (A). The comparison of cross-sectional frequency of LLDAS between belimumab and telitacicept treatment (B). The lack of LLDAS achievement of belimumab and telitacicept (C). The difference of improvement of SLE parameters after treatment between belimumab and telitacicept (D-I).

Mechanism of action for telitacicept (By Figdraw).

Median and IQR of immunoglobulins among patients before and after treatment. Data are expressed as median and IQR. (a) Absolute values of IgA in patients receiving placebo or telitacicept (160 mg/week or 240 mg/week) at baseline and week 24. (b) Absolute values of IgG in patients receiving placebo or telitacicept (160 mg/week or 240 mg/week) at baseline and week 24. (c) Absolute values of IgM in patients receiving placebo or telitacicept (160 mg/week or 240 mg/week) at baseline and week 24. IgA, immunoglobulin A; IgM, immunoglobulin M; IgG, immunoglobulin G; IQR, interquartile range.

A – Alopecia areata involving front of the head before treatment. B – Hair regrowth in the alopecic patches after treatment with telitacicept for 6 weeks. C – Prominent hair regrowth after treatment with telitacicept for 24 weeks